Skip to content

Boltz secures $110M Series A to accelerate AI-driven drug discovery

·StartupReader editorial desk· 2 min readReviewed by our editors
FUNDING. $110M raised by Boltz, AI-driven drug discovery. Stage: Series A.

London-based Boltz, an AI-focused drug discovery startup spun out of MIT, has raised $110 million in Series A funding less than a year after emerging from stealth. The capital will expand its team of 40 AI researchers based in King’s Cross, London, as the company scales its proprietary models to accelerate molecule design and preclinical testing.

The round comes as investors increasingly back AI solutions in pharma, where high costs and long development cycles have made efficiency a key focus. Boltz’s quick rise—from stealth to a major Series A in under 12 months—aligns with broader momentum in AI-driven biotech, though its $110 million valuation is still lower than recent rounds like Namespace’s $42 million Series B (covered here on 5 October). The funding also reinforces London’s growing role as a hub for life sciences startups, particularly those using AI, following earlier-stage raises like LO:TECH’s $12 million Series A (2 November).

While Boltz hasn’t named its backers, the round’s size suggests strong support from biotech-focused VCs or corporate partners—a common trend in pharma-adjacent startups. The next step will be turning AI-generated insights into clinical-stage drugs, a challenge even well-funded companies like Spiko faced when scaling spacetech infrastructure (covered 6 October). Boltz’s focus on computational drug design may provide a clearer path forward, but the pharma industry’s cautious approach to new technologies could slow partnerships.

For founders watching AI in biotech, Boltz’s progress highlights the need to balance speed with scientific validation—a factor likely to influence future funding trends in the sector.

Sources: tech.eu

“The funding round reflects investor bets on AI’s potential to cut pharma development timelines—just as London strengthens its position as a life sciences innovation center.”
— StartupReader
ShareLinkedInXWhatsApp

One of the funding rounds reported in the week of 16–22 November 2026. See every round that week.

Read the original reporting

The outlets below did the original reporting.

Related briefs

This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.